1. <track id="afjae"></track>

      1. <acronym id="afjae"></acronym>
        <optgroup id="afjae"></optgroup>

        首頁 > 新聞資訊 > 西方最新研究成果:激素替代療法會導致乳腺癌
        產品類別 / CATEGORY
        聯系我們 / CONTACT US

        北京譯海騰飛翻譯公司

        聯系電話:010-81534401,65677906

        公司傳真:010-65677906

        項目經理:13241835386

        聯系信箱:81534401@163.com

        聯系地址:北京市朝陽區南郎家園1號大北寫字樓512室(國貿橋東南角,緊鄰招商局、海航大廈)

        郵政編碼:100022

        公司網址:http://www.msmaggi4goa.com

        新聞資訊
        西方最新研究成果:激素替代療法會導致乳腺癌
        編輯:北京譯海騰飛翻譯公司   發布時間:2018-11-01

        Hormone replacement therapy can triple the risk of breast cancer, the biggest ever study has found, following more than a decade of controversy.

        史上最大研究發現,經過十多年的爭議,激素替代療法可能使患乳腺癌的風險增加三倍。

        Last year the National Institute of Health and Care Excellence(Nice) changed guidance to encourage more doctors to prescribe HRT claiming too many menopausal women had been left suffering in silence.

        去年,國家卓越健康與護理研究所(The National Institute of Health and Care Excellence ) 修改指南,鼓勵更多的醫生在開出激素替代療法時要聲明許多更年期婦女都因此而留下默默忍受痛苦。

        HRT is used to treat uncomfortable symptoms of the menopause– such as hot flushes, migraines, disrupted sleep, mood changes and depression – by topping up the decreased levels of hormones produced by the body.

        激素替代療法用來治療更年期不適癥——比如潮熱、偏頭疼、失眠、脾氣大、無精打采----身體產生的激素下降水平達到最高值。

        But doctors were reluctant to prescribe it after a study in 2002 suggested it could raise the risk of cancer, a claim later widely disputed.

        但是2002年的一項研究認為激素替代療法可能會增加患癌的危險,之后,醫生們都不太愿意用這種療法了,這項聲明后來引起了廣泛的爭議。

        Now new findings by the?Institute of Cancer Research and Breast Cancer Now suggest the original risk had actually been underestimated.

        現在,國家卓越健康與護理研究所的新發現認為,原說的風險實際上被低估了。

        A study of 100,000 women over 40 years found those who took the combined oestrogen and progestogen pill for around five years were 2.7 times more likely to develop cancer compared to women who took nothing, or only the oestrogen pill.

        通過對40歲以上的100,000名婦女的研究,發現那些同時服用雌激素和孕激素藥丸的人大約在五年時間內發展成癌癥的可能性是那些沒有服用或只服用孕激素藥丸的人的2.7倍。

        The risk rose to 3.3 times for women who took the drugs for 15 yearsor more.

        那些服用這兩種藥15年或以上的婦女,其風險高達3.3倍。

        Around 14 in 1,000 women in their 50s are expected to develop breast cancer, but that rises to 34 in 1000 for women taking the combined pill, the study suggests.

        這項研究認為,大約有14/100050歲的婦女將會患乳腺癌,但如果同時服用這兩種藥,那么將會有34/1000的婦女會患乳腺癌。

        Our research shows that some previous studies are likely to have underestimated the risk of breast cancer with combined oestrogen-progestogen HRT,” said study leader Professor Anthony Swerdlow, of The Institute of Cancer Research.

        癌癥研究所的項目負責人AnthonySwerdlow教授說“我們的研究表明,前期的某些研究可能低估了激素替代療法所帶來的患乳腺癌的風險,即同時服用雌激素和孕激素藥丸?!?/span>

        We found that current use of combined HRT increases the risk of breast cancer by up to threefold, depending on how long HRT has been used.

        “我們發現當前使用的同時服用激素的激素替代療法加大了患乳腺癌的風險,而且風險高達三倍,(當然)這要取決于激素替代療法使用的多長時間。

        Our findings provide further information to allow women to make informed decisions about the potential risks and benefits of HRT use.”

        “我們的發現進一步提供信息,讓婦女在做出決定時具有知情權,知道使用激素替代療法潛在的風險和益處?!?/span>

        Women taking the oestrogen-only pill have no greater risk

        只服用孕激素藥丸的婦女,則沒有這么大的風險。

        HRT?was first developed in the 1940s and was first made available to women in Britain in 1965.

        激素替代療法發端于1940s年代,最初在英國婦女身上使用時在1965年。

        However in 2002 the British Millennium Women Study published findings claiming that HRT raised the risk of cancer. Many doctors immediately withdrew prescriptions while the Medical Health care and Regulatory Agency (MHRA) issued new guidance recommending all womenbe given the "lowest effective dose should beused for the shortest time."

        然而2002年英國千禧婦女研究發表了研究結果,聲稱激素替代療法加大了患乳腺癌的風險。許多醫生立刻取消了這種處方,醫療保健和監管機構(MHRA)發布新的指導綱要,推薦給予所有婦女“應該使用最低有效劑量,服用時間最短?!?/span>

        Since then the number of women taking HRT has more than halved with around one in 10 eligible patients now using thedrugs, approximately 150,000 women.

        之后,采取激素替代療法的女性數量減少一半多,即10個符合條件的患者中大約有1人仍在服用這兩種藥物,(總數)大約有150,000名婦女。

        More recently a review by Imperial College and a 10-year studybyNew York University found no evidence of a link, adding further to the confusion and last year the National Institute for Health and Care Excellence (Nice) changed itsguidance?to encourage doctors to offer HRT claiming one million women were suffering in silence.

        帝國理工學院(ImperialCollege)最新發布的一項評論,以及紐約大學的一項耗時10年的研究沒有發現進一步引起慌亂的關聯性證據;去年,國家卓越健康與護理研究所(Nice)修改指南,鼓勵醫生在采取激素替代療法時要聲明有一百萬婦女因此種療法而默默遭受痛苦。

        At the time Nice said that the cancer risk was 27 in 1,000 so the new research, which followed 100,000 women for 40 years,increases that risk by 54 per cent.

        當時,國家卓越健康與護理研究所說,患癌危險是27/1000,而新的研究跟蹤研究了100,000名婦女40年,結果是患癌危險高達54%。

        The health watchdog said that the new study should not change how doctors prescribed HRT.

        We found that current use of combined HRT increases the risk of breast cancer by up to three fold, dependingon how long HRT has beenused” ----Professor Anthony Swerdlow, Institute of Cancer Research

        衛生監督機構說,新的研究不應該改變醫生怎樣開出HRT處方。

        “我們發現當前使用的同時服用兩種激素藥的HRT加大了患乳腺癌的危險,而且高達3倍,這要取決于HRT方法使用的多長時間?!?/span>---引自癌癥研究所的AnthonySwerdlow教授。

        Professor Mark Baker, director of the Centre for Guidelines at NICE,said: “As with Nice guidance this study recognisesthere is no increased risk of breast cancer with oestrogen-only HRT but the combined HRT can be associated with anincreased risk ofbreast cancer.

        國家卓越健康與護理研究所指導綱要中心主任MarkBaker教授,說:“至于國家卓越健康與護理研究所的指導綱要,這項研究承認如果只服用雌激素的HRT沒有加大患乳腺癌的風險,但是如果同時服用兩種激素的HRT可能與增加患乳腺癌的風險有關系?!?/span>

        The guideline makes clear that menopausal women should be informed that the impact of HRT on the risk of breastcancer varies with the type of HRT used.

        “指導綱要清楚的表明應該告知更年期婦女HRT產生的患乳腺癌的風險影響因HRT使用的類型的不同而不同。

        The message from our guidance to women isclear– talk about the menopause with your clinician ifyou need advice on your symptoms - it’s very important to discuss the options to find what might helpyou.”

        “我們給婦女的指導綱要中的信息很清楚----如果你需要得到關于你的癥狀的建議時,要講你的更年期告訴給臨床醫生----討論哪種選擇有助于你是非常重要的?!?/span>

        The new study also found that the risk declined when women stopped taking HRT and there was no danger at all for women only taking oestrogen, which accounts for half of all prescriptions.

        最新研究也發現,當婦女停用HRT時風險就降低了,對于只服用雌激素的婦女來說,根本沒有任何危險,這占有所有處方的一半之多。

        Baroness Delyth Morgan, chief executive at Breast Cancer Now, said: “Whether to use HRT is an entirely personal choice, which is why it’s so important that women fully understand the risks and benefits and discuss them with their GP. We hope these findings will help anyone considering the treatment to make an even more informed decision.

        “今日乳腺癌”機構的董事長BaronessDelythMorgan說:“是否采用HRT完全是個人的選擇,這是為什么說婦女要完全了解并與從業醫生討論此法的風險和益處是如此的重要。我們希望這些發現有助于任何想考慮此種治療的人,并作出一個具有更多知情權的決定?!?/span>

        On balance, some women will feel HRT to be a necessity. But in order to minimise the risk of breast cancer during treatment, it is recommended that the lowest effective dose is used for the shortest possible time.

        “總的來說,有些婦女會覺得HRT是必需的方法。但為了在治療期間減小患乳腺癌的風險,建議大家服用最小的有效劑量,服用時間盡可能最短。

        The good news is that the increased risk of breast cancer begins to fall once you stopusing HRT.”

        “好消息是,一旦停用HRT,患乳腺癌的風險就開始降低了”


        成长免费视频

          1. <track id="afjae"></track>

            1. <acronym id="afjae"></acronym>
              <optgroup id="afjae"></optgroup>